FY2024 EPS Estimates for Eyenovia Increased by HC Wainwright

Eyenovia, Inc. (NASDAQ:EYEN) – Research analysts at HC Wainwright lifted their FY2024 EPS estimates for Eyenovia in a research note issued on Wednesday, November 13th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.51) per share for the year, up from their previous forecast of ($0.67). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.09) EPS, FY2025 earnings at ($0.48) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $0.56 EPS.

Other equities analysts also recently issued research reports about the stock. William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a research note on Friday. Brookline Capital Management reiterated a “hold” rating on shares of Eyenovia in a research report on Friday.

Eyenovia Stock Down 70.0 %

Shares of NASDAQ EYEN opened at $0.10 on Friday. The company has a 50 day simple moving average of $0.49 and a 200 day simple moving average of $0.71. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.27. Eyenovia has a 1 year low of $0.09 and a 1 year high of $2.57. The firm has a market cap of $6.53 million, a PE ratio of -0.14 and a beta of 1.75.

Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter last year, the company posted ($0.18) EPS.

Institutional Investors Weigh In On Eyenovia

Several large investors have recently added to or reduced their stakes in EYEN. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eyenovia during the 2nd quarter valued at about $26,000. Ground Swell Capital LLC purchased a new position in shares of Eyenovia in the 2nd quarter worth about $27,000. Nations Financial Group Inc. IA ADV increased its position in shares of Eyenovia by 24.4% during the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock valued at $30,000 after acquiring an additional 10,000 shares in the last quarter. Financial Management Network Inc. bought a new position in Eyenovia during the 3rd quarter valued at about $39,000. Finally, SkyView Investment Advisors LLC purchased a new stake in Eyenovia during the 2nd quarter valued at $87,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Insider Buying and Selling at Eyenovia

In other Eyenovia news, CEO Michael M. Rowe bought 50,000 shares of Eyenovia stock in a transaction dated Monday, August 26th. The stock was bought at an average cost of $0.57 per share, with a total value of $28,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 82,927 shares in the company, valued at approximately $47,268.39. The trade was a 151.85 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 7.10% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.